UNC Lineberger Comprehensive Cancer Center
Trial Pipeline
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
NCT07069595
Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies
NCT07292818
Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia
NCT07278557
Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
NCT07389967
Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
NCT07313306
Medically Tailored Meals for Kids
NCT06814795
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
NCT07225114
Using Tailored mHealth Strategies to Promote Weight Management Among Adolescent and Young Adult Cancer Survivors
NCT06848491
Consumer Perceptions of Alcoholic Beverages
NCT07226271
Perceived Effectiveness of Vaping Prevention Ads Among Adolescents and Young Adults
NCT07116837
Dissemination of BREASTChoice AIM1-B
NCT07396766
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
NCT07025785
Expanding the Support of Family Caregivers of Diverse Patients With Cancer and Diabetes
NCT07061652
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
NCT06896162
mPATH-Cloud for Colorectal Cancer Screening
NCT06441487
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
NCT06860880
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
NCT06902376
Implementation of an Oral Chemotherapy Adherence Intervention
NCT06989489
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
NCT06727773
Designing Visual Tools to Enhance Cancer Surgeon Decision-making
NCT06965192
Digital Art Therapy for Young Cancer Survivors
NCT06789666
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
NCT06902311
VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients
NCT06878547
Effectiveness of Central Oncology Navigation and the Use of an ORN
NCT06618274
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
NCT06483555
Rehabilitation Outcomes Study
NCT06674889
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
NCT06855654
A Novel Approach Utilizing Organ Specific Age Proteomics
NCT06789653
Multimedia Aid for Genetic Testing in Gynecologic Oncology
NCT07084168
BREAST Choice Decision Tool R21 - AIM2
NCT06817226
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
NCT06305299
Autologous CAR-T Cells Targeting B7-H3 in PDAC
NCT06158139
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
NCT06347068
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
NCT06296368
Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment
NCT04743674
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
NCT06090864
UNC Metastatic Cancer Radiation Therapy Registry
NCT06306924
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
NCT06096038
Promoting CT Engagement for Pancreatic Cancer With App
NCT06252545
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
NCT04700527
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
NCT07214610
Improving Thoracic Surgical Care Using Electronic Patient-Reported Outcomes (ePROS)
NCT06075316
GRID Therapy for Extremity Soft Tissue Sarcoma
NCT06073067
The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment
NCT06096623
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT05542407
Brain Slice Explants to Predict Drug Response in Brain Tumors
NCT05978557
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
NCT05620342
Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies
NCT05743426
Comparison of CE-DBT and MRI in Patients With Known Breast Lesions
NCT05754749
Young Adult Infusion Space Experience Satisfaction Survey
NCT05720546
Evaluation of Child Care Staff Weight Management Program
NCT05656807
Adaptation of a Values Assessment Tool
NCT07068477
Study of Trilaciclib and Lurbinectidin
NCT05578326
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
NCT05366179
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
NCT05440929
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
NCT05472792
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
NCT05145400
UNC Childhood, Adolescent, and Young Adult Cancer Cohort
NCT05096923
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
NCT04564989
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
NCT04223765
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT04099290
MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets
NCT04073966
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
NCT04083495
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
NCT03977233
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
NCT03721068
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
NCT03769415
Registry for Adults With Plasma Cell Disorders (PCD's)
NCT03717844
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT03454035
UNC Pleural Fluid Registry
NCT05620329
Registry of Older Patients With Cancer
NCT01137825
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
NCT01137643
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
NCT01000883
Physical Activity Centers Empowerment
NCT06411756
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
NCT05911321
Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers
NCT05823740
Impact of Financial Incentives
NCT05744960
Impact of Standing Orders Optimization
NCT05742386
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05498220
Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
NCT05926024
Pembrolizumab Plus Olaparib in LA-HNSCC
NCT05366166
Patient Related Outcomes for Gynecologic Radiation Oncology
NCT04753086
PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology
NCT05592665
Immuno-Oncology Database and Bioregistry
NCT04656873
Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
NCT04670068
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
NCT04548648
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
NCT03978624
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
NCT03529422
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
NCT04134325
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
NCT03696784
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
NCT03672318
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
NCT03602157
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
NCT03264131
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
NCT03174275
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
NCT02690545
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
NCT02663297
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
NCT03016377
Little Cigar and Cigarillo Warnings for Youth
NCT06413797
Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors
NCT06171945
Impact of E-Cigarette Prevention Messages on Adolescents
NCT05985538
Physical Activity and Healthy Eating Among Young Adult Cancer Survivors
NCT05887401
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 62 |
| Phase 2 | 81 |
Therapeutic Areas
What the Pipeline for UNC Lineberger Comprehensive Cancer Center Shows
According to the ClinicalTrials.gov registry, UNC Lineberger Comprehensive Cancer Center is linked to 374 US clinical trials across every stage of research activity. Of those, 298 studies are currently recruiting — about 80% of the sponsor's indexed portfolio — and 52 are already marked complete, representing roughly 14% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for UNC Lineberger Comprehensive Cancer Center reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 143 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for UNC Lineberger Comprehensive Cancer Center is Breast Cancer with 29 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.